Adagene to Present at Stifel’s 2025 Virtual Targeted Oncology Forum
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 07 2025
0mins
Source: Globenewswire
Adagene's Participation in Oncology Forum: Adagene Inc. will have its CEO, Peter Luo, participate in one-on-one investor meetings and provide a corporate update at Stifel’s 2025 Virtual Targeted Oncology Forum on April 8-9, with a webcast available for 30 days.
Overview of Adagene's Technology and Pipeline: Adagene is a clinical-stage biotechnology company focused on antibody-based cancer immunotherapies, utilizing its SAFEbody technology to enhance safety and targeting in treatments, with its lead program ADG126 currently in clinical trials for colorectal cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
